Corporate

QUIBIM se posiciona en el mercado americano analizando hábitats tumorales y enfermedades difusas hepáticas

Ha cerrado acuerdos con la compañía EnvoyAI y ha abierto oficina en Silicon Valley

QUIBIM sigue creciendo en el desarrollo de algoritmos de análisis de imágenes médicas basados en modelos biológicos y en inteligencia artificial. La compañía, que cerró el año 2017 con un crecimiento del 500% en sus métricas de negocio (número de análisis y facturación), ha avanzado con la expansión al mercado americano de sus algoritmos para cáncer y enfermedades difusas hepáticas. Entre los hitos más relevantes, además de la reciente apertura de oficina en Palo Alto (Silicon Valley, California), QUIBIM ha establecido una alianza con la empresa EnvoyAI, dedicada a la integración y distribución de algoritmos de inteligencia artificial para imágenes médicas. EnvoyAI fue adquirida el año 2016 por TeraRecon, empresa con un software de visualización radiológica que se encuentra actualmente instalado en el 85% de los hospitales de Estados Unidos.

Estos algoritmos de QUIBIM para el mercado americano, ahora mismo en proceso de certificación por la Food and Drug Administration (FDA), caracterizan tanto las diferentes subregiones o habitats internos de un tumor como analizan por biopsia virtual hepática las enfermedades difusas tipo esteatosis, sobrecarga de hierro, inflamación y fibrosis.

En el ámbito de la oncología, QUIBIM proporciona una metodología que extrae datos de textura, celularidad y proliferación vascular en los tumores, siendo aplicable en lesiones cerebrales, de mama, próstata, hígado y recto, entre los principales tumores sólidos. Esta metodología puede aplicarse a las imágenes de Resonancia Magnética y Tomografía Computarizada, proporcionando una información pronóstica sobre la evolución de los pacientes y su respuesta a los diferentes tratamientos.

En el ámbito de las enfermedades difusas hepáticas, QUIBIM proporciona un algoritmo para realizar una biopsia virtual hepática, sin dañar al paciente, a partir de las imágenes de Resonancia Magnética y extrayendo la proporción de grasa, concentración de hierro y proporciones de inflamación y fibrosis hepática. Este análisis es de especial relevancia para el estudio y seguimiento de la esteatohepatitis y la hemocromatosis, y en la evaluación de la historia natural y su modificación por el tratamiento en las hepatopatías crónicas y la cirrosis. Actualmente esta información se obtiene a partir de biopsias convencionales, lo que implica un riesgo para el paciente y un sesgo inherente al procedimiento dado que sólo se obtiene información del lugar de la punción, mientras que el algoritmo de QUIBIM permite obtener información de todo el hígado de manera segura.

En palabras de su CEO, el Dr. Ángel Alberich-Bayarri, resumiendo estos hitos “estamos en una fase muy intensa de la compañía y con un crecimiento significativo, y gracias al esfuerzo del equipo hemos podido acelerar varios hitos que teníamos previstos en fases más tardías, como por ejemplo la alianza con EnvoyAI, la solicitud a FDA y la apertura de oficina en EEUU. Los algoritmos que hemos seleccionado para este mercado aportan un valor diferencial que ya hemos podido verificar, recibiendo solicitudes desde algunos hospitales antes de iniciar acciones comerciales.”

QUIBIM es una empresa biotecnológica nacida en Valencia y está especializada en la extracción de información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear, mediante técnicas originales y avanzadas de procesamiento computacional. Estos parámetros extraídos reciben el nombre de Biomarcadores de Imagen y aportan rasgos extraídos de las imágenes médicas, relacionadas con procesos biológicos normales, enfermedades o respuestas terapéuticas.

Además, el equipo ha desarrollado la plataforma QUIBIM Precision® de análisis de imágenes médicas en la nube, que puede instalarse en versiones privadas para hospitales y para compañías farmacéuticas que desarrollen ensayos clínicos. A partir de imágenes de rayos X, Ecografía, TAC, Resonancia Magnética o PET, QUIBIM es capaz de aplicar algoritmos avanzados de análisis con metodologías basadas en procesamiento por GPU (unidades de procesamiento gráfico), Machine Learning o Big Data. El software de QUIBIM permite aportar una mayor información en los diagnósticos y poder evaluar de forma temprana la respuesta a los tratamientos farmacológicos. La compañía fue seleccionada en 2017 para el programa SME Instrument Fase II de la Comisión Europea.

INTERVIEW | Is Quantitative Imaging Analysis in Clinical Research Cost Effective?

Today we are interviewing Jose García, Project Manager of Quibim’s clinical trials, as well as Ángel Alberich-Bayarri, CEO and founder of Quibim.

We have discussed the benefits of quantitative imaging analysis in previous episodes, but in this interview we are analyzing the cost effectiveness of this solution.  Ángel explained that if we take a long term holistic approach, we would be able to have a real time monitoring of the statistical analysis of the study.  This alone saves Sponsors potentially millions of dollars, but even beyond that, patient selection for future or current clinical trials can be more efficiently targeted when utilizing imaging biomarkers.

Jose also explained that the utilization of Quibim’s technology is a natural advancement in the evolution of how we conduct and analyze clinical research studies.  Although we are at the forefront of this revolution, costs are going to continue to drop as the required technology for real time quantitative analysis advances.  Jose used the analogy of dispersed light versus the precision of a laser beam and how Quibim’s capabilities more accurately reflect the latter.

In regards to the macro-analysis of cost saving measures, centralizing the process of qualitative and quantitative image reading services as it becomes increasingly quantitative due to the parameters being extracted.  Artificial intelligence and algorithms will also play a large role in the quantitative analysis and will assist the qualitative readings of humans, such as radiologists.  The more we can automate the quantitative process, the greater the cost savings are made available to the study sponsors.

Towards the end of the interview, we discussed in silico studies, where, by utilizing a “digital twin” of an actual study subject, sponsors could in theory create a simulated clinical trial and determine outcomes while reducing potential risk to human participants, specifically in phase 1 trials primarily.  Quibim is at the forefront of this movement, and we will focus on this topic in our next episode!

INTERVIEW | The Inefficiencies of Qualitative Imaging Analysis in Clinical Research

In this episode of Quibim Blog, CEO and founder Ángel Alberich-Bayarri sits down with Dan Sfera and discusses the differences between quantitative and qualitative imaging analysis when it comes to clinical research.  Some of the more common therapeutic indications that involve image analysis include: oncology, central nervous system disorder, and respiratory illnesses.  Ángel made a great analogy in this interview of artificial intelligence, the algorithms that power Quibim’s quantitative imaging capabilities, being similar to GPS when it comes to assisting drivers in navigating during their commutes.  Algorithms in imaging analysis are similar in the sense that they are tools to assist the imaging analysis readers (radiologists) in making quantitative diagnosis’ rather that the current industry standard of qualitative assessments.  That seems to be the key benefit of Quibim’s value proposition: taking a subjective diagnosis and adding a quantitative component to it in order to allow the clinicians to make better informed decisions.

INTERVIEW | Biomarker Imaging Analysis and Real Time Clinical Trial Capabilities

In this episode, Quibim CEO, Ángel Alberich-Bayarri discusses some of Quibim’s technological capabilities which makes real time clinical trial safety monitoring and efficacy assessments practical and possible.  Angel discusses the importance of analyzing biomarkers in the form of images and how this method can provide several advantages over the traditional blood biomarker analysis.  Join our mailing list to be notified of future webinars from Quibim!

INTERVIEW | A Clinical Research Entrepreneur’s Story and The Loss Of CRO Dominance In Research

Quibim founder Ángel Alberich-Bayarri and Dan Sfera discuss Quibim’s origins, and the entrepreneurial spirit which is necessary to have a successful startup company in the Life Sciences industry. Dan and Ángel also discuss the emergence of artificial intelligence in the clinical research space as well as how algorithms can help identify therapeutic effect of a particular treatment on a medical condition. The interview segways into the Precision Medicine Congress Conference just held in San Fransisco in January of 2018, an event which Ángel and Quibim were well received at due to their innovative technology and strong leadership team. Finally, the interview discusses the emergence of sophisticated and technologically capable vendors, such as Quibim itself, and how their emergence is allowing Sponsors to bring more of their research initiatives in house. It will certainly be an interesting clinical research landscape to keep an eye on this year and Quibim Blog will continue producing these interviews for you!

INTERVIEW| JP Morgan 2018 Healthcare Conference Recap: AI and Blockchain

Dan Sfera had the opportunity to interview Quibim founder, Ángel Alberich-Bayarri live on location in San Francisco, CA for the 2018 JP Morgan Healthcare Conference.  Not only was Quibim proud to showcase some of it’s imaging and algorithmic capabilities and technologies, but we were also able to network and collaborate with other vendors from within the life sciences industry in order to bring better clinical research solutions to our customers and patients!  For anyone not able to attend the conference in person, we hope that by watching this video we could give you a glimpse into some of the trending topics that is of interest to the greater pharmaceutical and medical device industries.  The two most popular topics that kept popping up at this year’s conference: Artificial Intelligence and Blockchain Technology. We hope to provide another recap after Quibim showcases at yet another industry conference also in San Francisco later this month. Stay tuned!

INTERVIEW | The Differences Between Blood and Imaging Biomarkers in Clinical Research

We were able to site down with Quibim’s Chief of Research and Development, Fabio García.  Fabio is a software engineer by education who happened to have a passion for medicine, and has joined Quibim to help develop new products as they relate to identifying and analyzing imaging biomarkers.

In this interview we discussed the differences between blood and imaging biomarkers, the advantages and disadvantages of both, and the benefits of both working together simultaneously to provide optimal diagnosis in a clinical or research setting.

A biomarker is a way of identifying a biological process in the body that you can measure and quantify.  There are currently two ways of identifying and analyzing biomarkers: blood and imaging.

Fabio is excited in regards to what the future holds for imaging biomarkers in clinical trials, and as the technology becomes more cost effective, he believes the industry will continue further adoption of this novel diagnostic technique.

INTERVIEW | Quibim’s CTO Explains The Various Technological Capabilities For Biomarker Analysis

Quibim’s Chief Technology Officer, Rafael Hernández, sits down to explain how he got started with Quibim, the importance of biomarkers in clinical research, and some of the technology behind Quibim’s service offerings.

The key takeaway for me was the differentiation between the algorithms used to analyze the biomarker images, and the customizable software utilized to interface with the images.

Another point of interest is the storing capabilities of the images on a HIPAA compliant cloud server, or, on an equally secure local server at the location of the particular client, for example, a local hospital.

Finally, patient-centricity is at the root of these innovations. Quibim’s technology allows for encrypted and completely de-identified biomarker images that allow the Sponsors to analyze results without compromising the privacy of the individual patients. Furthermore, by pioneering breakthrough diagnostic services, Quibim is contributing directly to medical advances and breakthroughs that we can all benefit from in the near future!

INTERVIEW | Irene Mayorga Discusses Biomarkers and Clinical Research Image Analysis

Irene Mayorga, Clinical Trial Manager from Quibim discusses the emergence of biomarkers in clinical trials and how this will affect medical breakthroughs in the near future.

One of the more interesting things discussed with Quibim’s Clinical Trial Manager was the sophisticated process of analyzing images such as brain and lung scans with proprietary software that is then easily accessible by Sites and CRO’s alike through their web browsers.  Streamlining the receipt of the image scans from the various vendors across the globe, Quibim provides results and analysis as well as post processing of images and re-uploading the results to the Site/CRO portal.

Quibim is able to advance post process the images through quantifiable biomarkers, all in real time with simple access for the Sponsor/CRO/Trial Sites.  Biomarkers are important to analyze because they provide real time analytics to Sponsors who can analyze the process of the trial in real time.  Furthermore, the data being collected is added to the risk based monitoring components for any given trial that requires image results.  Study timelines can be reduced and save Sponsors millions of dollars per clinical trial due to these real time result and biomarker analysis.  Alternatively, clinical studies can be adapted in real time to enhance the safety profile of the subjects, or to manipulate the dosage of the investigational product when appropriate.

Quibim’s technology can apply to lung, bone, liver and other forms of cancer associated tumors due to the progression or regression of a particular tumor, again through biomarker analysis utilizing micro architecture analysis.  Allowing for virtual biopsies, as an example, liver tumors can be analyzed with greater precision and minimal invasiveness to study participants.  This has applications outside of clinical research as well, with the ability to save insurance companies a significant amount of associated costs.

Going forward, the clinical research industry will experience an explosion of diagnostics and device studies.  Quibim is well equipped to play a big role in the infrastructure of the safety and analysis of several critical endpoints when it comes to biomarkers and image analysis.

 

 

025-FEDER2-declaracion14-20

El proyecto QUIBIM recibe la ayuda del IVACE-PREPARACIÓN DE PROPUESTAS PARA CONVOCATORIAS H2020

QUIBIM es un proyecto empresarial de alto impacto social y sanitario, que extrae información cuantitativa de las imágenes médicas radiológicas, mediante técnicas innovadoras y avanzadas de procesado computacional, con el objetivo de mejorar los procesos de diagnóstico de enfermedades con alta incidencia y evaluar adecuadamente los cambios que producen los tratamientos farmacológicos en el organismo.

Durante 2016 el proyecto de internacionalización QUIBIM ha recibido la ayuda IVACE – PREPARACIÓN DE PROPUESTA PARA CONVOCATORIAS DEL PROGRAMA MARCO  H2020 DE INVESTIGACIÓN E INNOVACIÓN 2014-2020  (IMAPEA/2016/38) con el apoyo del Fondo Europeo de Desarrollo Regional (FEDER) con el objetivo de presentar nuestros servicios de diagnóstico y análisis avanzado de imagen médica y dar a conocer nuestra plataforma de análisis QUIBIM Precision® para el análisis de Biomarcadores de Imagen.

IVACE_QUIBIM